January 13, 2021

Press release

FluoGuide gets green light to proceed to third dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma

Copenhagen, Denmark, 13 January 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee... [Read more]

December 17, 2020

Press release

FluoGuide gets green light to proceed to second dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma

Copenhagen, Denmark, 17 December 2020 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee... [Read more]

November 26, 2020

News

FluoGuide’s presentation at Økonomisk Ugebrev’s Life Science event is now available

Copenhagen, Denmark, 26 November 2020 – Yesterday, FluoGuide A/S (“FluoGuide” or the “Company”) presented at Økonomisk Ugebrev’s Life Science event. The... [Read more]

November 20, 2020

Press release

FluoGuide A/S publishes interim report for the period January – September 2020

Copenhagen, Denmark, 20 November 2020 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January... [Read more]

November 9, 2020

Press release

First patient enrolled in the phase I/II clinical trial testing FG001 in patients with high grade glioma

Copenhagen, Denmark, 9 November 2020 – FluoGuide A/S (“FluoGuide” or “the Company”) is pleased to inform that the first patient today... [Read more]

October 14, 2020

Press release

FluoGuide A/S presents at BioStock Live

Copenhagen, Denmark, 14 October 2020 – FluoGuide A/S (“FluoGuide” or “the Company”) presents at BioStock Live on Thursday 15 October 2020... [Read more]

September 21, 2020

Press release

FluoGuide appoints Henrik Moltke as Chief Financial Officer

Copenhagen, 21 September 2020 – FluoGuide A/S (“FluoGuide” or “the Company”) today announces the appointment of Henrik Moltke as Chief Financial... [Read more]

September 3, 2020

Press release

FluoGuide announces regulatory approval from Danish Medicines Agency to commence Phase I/II clinical trial with FG001 in guiding surgery of high grade glioma (including glioblastoma)

Copenhagen, Denmark, 3 September 2020 – FluoGuide A/S (“FluoGuide” or “the Company”) is pleased to announce that the company has received... [Read more]

July 6, 2020

Press release

FluoGuide A/S submits phase I/II Clinical Trial Application

Copenhagen, Denmark, 6 July 2020 – FluoGuide A/S (“FluoGuide” or “the Company”) today submitted a Clinical Trial Application for the proof-of-concept... [Read more]